SUGAMMADEX versus neostigmine after ROCURONIUM continuous infusion in patients undergoing liver transplantation by Deana, C. et al.
RESEARCH ARTICLE Open Access
SUGAMMADEX versus neostigmine after
ROCURONIUM continuous infusion in
patients undergoing liver transplantation
Cristian Deana1*, Federico Barbariol1, Stefano D’Incà2, Livia Pompei3 and Giorgio Della Rocca4
Abstract
Background: Rapid neuromuscular block reversal at the end of major abdominal surgery is recommended to avoid
any postoperative residual block. To date, no study has evaluated sugammadex performance after rocuronium
administration in patients undergoing liver transplantation.
This is a randomized controlled trial with the primary objective of assessing the neuromuscular transmission recovery
time obtained with sugammadex versus neostigmine after rocuronium induced neuromuscular blockade in patients
undergoing orthotopic liver transplantation.
Methods: The TOF-Watch SX®, calibrated and linked to a portable computer equipped with TOF-Watch SX Monitor
Software®, was used to monitor and record intraoperative neuromuscular block maintained with a continuous infusion
of rocuronium. Anaesthetic management was standardized as per our institution’s internal protocol. At the end of
surgery, neuromuscular moderate block reversal was obtained by administration of 2 mg/kg of sugammadex or 50
mcg/kg of neostigmine (plus 10 mcg/kg of atropine).
Results: Data from 41 patients undergoing liver transplantation were analysed. In this population, recovery from
neuromuscular block was faster following sugammadex administration than neostigmine administration, with mean
times±SD of 9.4 ± 4.6 min and 34.6 ± 24.9 min, respectively (p < 0.0001).
Conclusion: Sugammadex is able to reverse neuromuscular block maintained by rocuronium continuous infusion in
patients undergoing liver transplantation. The mean reversal time obtained with sugammadex was significantly faster
than that for neostigmine. It is important to note that the sugammadex recovery time in this population was found to
be considerably longer than in other surgical settings, and should be considered in clinical practice.
Trial registration: ClinicalTrials.gov NCT02697929 (registered 3rd March 2016).
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Background
Myoresolution plays a crucial role in laparotomic and lap-
aroscopic general surgery, including orthotopic liver trans-
plantation (OLT), where a deep level of neuromuscular
block (NMB) has been shown to provide better surgical
conditions [1, 2]. Deep NMB, defined as ≤2 responses
after post-tetanic stimulation (or ‘post-tetanic count’,
PTC), requires higher doses of a neuromuscular blocking
drug (NMBD), with a consequent higher risk of longer
and unpredictable recovery times regardless of the agent
used [3–5]. The use of NMBD at high dosages to achieve
deep NMB may also be associated with increased postop-
erative residual curarization (PORC) that leads to pulmon-
ary complications and may even hinder successful
extubation [6–8]. Both the administration of NMBD re-
versal agents at the end of surgery and the use of neuro-
muscular transmission (NMT) monitoring throughout the
surgical procedure are key factors to counteract the ad-
verse outcomes related to impaired neuromuscular trans-
mission after extubation [9–12].
International guidelines and expert opinions strongly
recommend NMT monitoring to optimize the dosage
and timing of both NMBD and reversal agent adminis-
tration, with the upshot of enabling early and safe extu-
bation. This is also strongly encouraged in OLT settings,
due to it being able to affect patient outcome directly as
well as being a cost-effective practice [13–18].
The pharmacokinetics and pharmacodynamics of
rocuronium bromide may be altered in patients with im-
paired liver function, resulting in a longer elimination
half-life, a slower recovery from NMBD and unpredict-
able behaviour for instance about onset time [19, 20].
The safety and speed of action of sugammadex has been
investigated and validated in different settings, including pa-
tients with liver disease undergoing liver surgery [21–23].
Fujita and colleagues demonstrated that sugammadex can be
effective for the reversal of NMBD after low dose rocuro-
nium continuous infusion in patients with liver disorders
undergoing liver resection surgery, with no differences be-
tween cirrhotic and non-cirrhotic patients, as supported by
comparable sugammadex recovery times between the two
groups of patients [24]. Similar results were recently obtained
by Abdulatif and colleagues who recorded a mean recovery
time of 3.1min for sugammadex given at a dose of 2mg/kg
for moderate block reversal in a cohort of patients with
chronic hepatitis C liver cirrhosis undergoing liver resection
surgery for neoplastic lesions [25].
However, patients with end-stage liver disease undergo-
ing OLT may present some features that make the
pharmacodynamics of rocuronium even more unpredict-
able; such features may include: extensive blood loss; need
for urgent surgery; long length of surgery; extensive fluid
shifts; large haemodynamic changes with consequent vari-
able organ perfusion (including emunctory organs).
To the best of our knowledge, no study has evaluated
sugammadex use after the continuous infusion of rocur-
onium during OLT. The primary objective of this study
was to measure the time interval from the administra-
tion of the NMBD reversal agent (sugammadex or neo-
stigmine) to a train-of-four ratio (TOFR) ≥ 0.9 (i.e., the
recovery time) in patients who had undergone OLT with
intraoperative continuous rocuronium infusion. The sec-
ondary objective was to determine possible relationships
between the recovery times of the two drugs with pre-,
intra- or postoperative variables.
Methods
This is a single centre, non-blinded, randomized controlled
trial approved by our Institution’s Ethics Committee “Comi-
tato Etico Unico Regionale-CEUR” of Academic Hospital “S.
Maria della Misericordia” (n° 2016-O-015-ASUIUD) and
registered at ClinicalTrials.gov (NCT02697929). This manu-
script adheres to the applicable CONSORT guidelines and
the study protocol conformed to the Declaration of Helsinki
ethical guidelines.
After Ethics Committee approval, we evaluated con-
secutive cases of OLT performed at the Academic Hos-
pital “S. Maria della Misericordia”, Udine, Italy. Written
informed consent was obtained before commencing
OLT; patients were then randomly allocated to the
sugammadex or neostigmine group using an online
computer-generated table. All clinical data were col-
lected in an Excel spreadsheet (Microsoft Excel for Mac,
Version 14.0.0, Microsoft Corporation, USA). Inclusion
criteria were as follows:
– Age > 18 years
– Neuromuscular transmission data acquired with
TOF-Watch SX Monitor Software® (Organon,
Dublin, Ireland. Version 1.2), from anaesthesia in-
duction until extubation
Exclusion criteria were as follows:
– American Society of Anesthesiologists (ASA) status > 3
– Neuromuscular disease
– NMBA other than rocuronium bromide used
– Body mass index (BMI) < 18 kg/m2 or > 40 kg/m2
– Pre-operative impaired renal function, defined as
an estimated glomerular filtration rate < 30 ml/
min/1.73 m2
– Incorrect dosage of reversal (50 mcg/kg for neostigmine
and 2mg/kg for sugammadex)
– An inner body temperature < 35 °C or thenar
temperature < 32 °C at reversal administration
– Haemodynamic instability defined as norepinephrine
dosage > 0.1 mcg.kg− 1.min− 1 and/or dobutamine > 3
mcg.kg− 1.min− 1 and/or epinephrine > 0.1
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mcg.kg− 1.min− 1 at the time of reversal
administration and/or mean arterial pressure < 60
mmHg and/or HR > 100 bpm
– Acidosis defined as an arterial pH < 7.30 at the time
of reversal administration
The last three exclusion criteria were also applied to
determine whether extubation at the end of surgery
could be attempted in the operating room in cases in
which no graft dysfunction was present.
The pre-operative data collected regarded: sex; age;
weight; body mass index (BMI); liver disease; model for
end-stage liver disease (MELD); liver function; and renal
function. The intra-operative data collected regarded:
duration of surgery; intra-operative blood losses; packet
red cells (PRC); fresh frozen plasma (FFP) and salvage
blood transfused; platelets (PLT) use; fibrinogen admin-
istration; net fluid balance; cold ischaemia time (CIT);
warm ischaemia time (WIT); total dose of rocuronium
administered; and total millilitres of crystalloids and col-
loids infused. Cardiac output, cardiac index and central
temperature (values obtained from the pulmonary artery
catheter) with thenar temperature at the time of reversal
administration were also recorded. Any adverse events
were reported in the anaesthesia sheet.
Anaesthesia was induced with propofol (1–1.5 mg/kg)
and fentanyl (3–5 mcg/kg) or alfentanil (7–15 mcg/kg)
after facial mask denitrogenation with FIO2 = 0.8. NMBD
(rocuronium 0.6 mg.kg based on lean body weight) was
administered at anaesthesia induction only after TOF
Watch SX® calibration (Organon, Dublin, Ireland). An-
aesthesia was maintained with sevoflurane (End Tidal
[ET%] targeted to keep the bispectral index in the 40–60
range) and the continuous infusion of remifentanil
(0.05–0.3 mcg.kg− 1.min− 1), while neuromuscular block
was maintained by continuous intravenous infusion of
rocuronium bromide (Esmeron® 50 mg/5 mL, MSD Italia
S.r.l., Roma) (0.3–0.6 mg.kg− 1.h− 1) to keep T1 < 1 0%.
Haemodynamic monitoring, using a pulmonary artery
catheter (CCOmbo catheter 777HF8; Edwards Life-
science, Irvine, California, USA), aimed to optimize
indexed oxygen delivery (DOI2 > 600 ml.min
− 1.m2) for
the first 6 h postoperatively. All OLT were performed
with the same surgical equipe dedicated to solid organ
transplant surgery.
As per our routine practice for NMT monitoring with
TOF-Watch, two electrodes were placed over the left
ulnar nerve at the wrist and the acceleration transducer
put on the thumb, together with a hand adapter that
immobilized the other fingers. Data were collected using
a dedicated computer and TOF-Watch SX Monitor Soft-
ware®, which registered the response to ulnar nerve
stimulation every 15 s. After anaesthesia induction, but
before rocuronium administration, the TOF-Watch SX
was calibrated. Once calibration was complete, the
rocuronium bolus for tracheal intubation was adminis-
tered and continuous infusion started.
At the end of surgery, reversal agents – sugammadex
2 mg/kg based on actual body weight (Bridion® 100mg/
mL, MSD Rome, Italy) or neostigmine 50 mcg/kg based
on adjusted body weight plus 10 mcg/kg of atropine
(Intrastigmina®, 0.5 mg/mL, Lusofarmaco S.p.a., Rozzano,
Italy) – were administered (according to randomization)
after the appearance of three consecutive T2 twitches
(the so called moderate neuromuscular block; T2) de-
tected by TOF Watch SX®. Recovery time was defined as
the time interval from the administration of the reversal
agent to the achievement of 3 consecutive measurements
of TOFR ≥ 0.9.
Our secondary objective was to analyse the main pos-
sible correlations between factors that may have influ-
enced sugammadex and neostigmine recovery time:
BMI; MELD; pre-operative and postoperative liver and
renal function; surgical procedure length; blood loss; in-
traoperative fluid balance; cold and warm ischaemia
time; total amount of NMBA delivered; millilitres of
crystalloid and colloid infused; CO and CI at the time of
reversal administration.
Statistical analysis
Illman and colleagues found a mean difference of 11.6
min between sugammadex and neostigmine recovery
times, administered when two twitches were detectable
and reversal considered as having occurred when
TOFR > 90% [26]. Considering a 1:1 treatment ratio and
an expected 5-min reduction in the sugammadex group,
with an alpha level of 0.05 and a power (1-ß) of 90%, the
calculated sample size was 16 subjects for each group.
Taking into consideration a potential dropout of 20%
and to increase the statistical significance, we decided to
enrol at least 20 subjects per group.
Descriptive statistics (mean and standard deviation for
quantitative variables, and absolute and relative frequen-
cies for qualitative variables) were calculated for each
group. To test for a difference in the recovery times be-
tween the two groups with respect to the primary ob-
jective, we implemented a two-sided unpaired t test as
well as an F-test to compare variances and to test
whether the t test assumptions were met. The same test
was applied to all remaining data. The alpha level of
statistical significance for all applied tests was 0.05. No
imputation of missing data was used in the analysis. Fi-
nally, to detect possible relationships between the recov-
ery times of the two drugs with other variables, we
performed both the Spearman rank and the Pearson cor-
relation tests, since differences, or a lack thereof, could
provide additional information.
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GraphPad Prism version 6.01 (GraphPad Software,
California, USA) was used for the final statistical
analysis.
Results
A total of 41 patients were enrolled onto the study: 21
were treated with sugammadex and 20 with neostigmine,
as shown in the study flowchart (Fig. 1). Baseline charac-
teristics and end-stage liver disease aetiology were com-
parable between the sugammadex and neostigmine
groups (Table 1). Furthermore, there were no statisti-
cally significant differences in pre-, intra- or postopera-
tive values regarding haemodynamics, liver and renal
function (Table 1 and 2).
The rocuronium onset times were similar between the
two groups at 195 ± 124 and 250 ± 123 s for the sugam-
madex and neostigmine groups, respectively (p = 0.20).
The total dose of rocuronium administered was 217 ±
61mg and 199 ± 74mg (p = 0.41) for the sugammadex
and neostigmine groups, respectively. The total amount
of reversal administered was 147 ± 25.5 mg and 3.7 ± 0.6
mg, respectively.
The mean core and thenar site temperatures of patients
treated with sugammadex, recorded at reversal adminis-
tration, were 37 ± 0.8 °C and 35.2 ± 1.3 °C, respectively;
whereas they were 36.6 ± 0.9 °C and 35.2 ± 1.4 °C in the
neostigmine group (core p = 0.29, thenar site p = 0.92).
The mean time from ceasing rocuronium infusion to
T2 was 57 ± 32 and 58 ± 25 min in the sugammadex and
neostigmine groups, respectively (p = 0.95). Mean recov-
ery times were significantly faster in patients treated
with sugammadex than neostigmine: 9.4 ± 4.6 min vs.
34.6 ± 24.9 min, respectively (p < 0.0001), as shown in
Fig. 2. Seven patients out of 21 (33%) in the sugamma-
dex group required more than 10min to achieve a
TOFR > 0.9. One patient in the neostigmine group was
an outlier with a recovery time > 100 min and as such
was not included in the mean recovery time calculation
(Fig. 2).
In the sugammadex group, 4 patients were extubated
at the end of surgery in the operating room (19%); this
occurred in 2 patients in the neostigmine group (10%,
p = 0.41). No difference was observed in the time from
ICU admission to extubation (245 ± 22min vs. 265 ± 62
min in the sugammadex and neostigmine groups, re-
spectively, p = 0.44).
Two patients (9.5%) in the sugammadex group and 1
patient (5%) in the neostigmine group underwent re-
operation within 24 h of extubation. In all cases, intra-
abdominal haemorrhage was responsible for the redo
surgery, and rapid sequence induction with succinylcho-
line was performed before administering cisatracurium.
The results of the coagulation tests performed before
and at the end of surgery were as follows: neostigmine
group: pre- vs. post operative INR: 2 ± 0.7 vs. 1.5 ± 0.4,
Fig. 1 Study flow-chart according to CONSORT. LTx, orthotopic liver transplantation; GFR, glomerular filtration rate
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respectively (p = 0.01); pre- vs. post operative aPTT ratio:
1.5 ± 0.5 vs. 1.2 ± 0.2, respectively (p = 0.04). The same
tests relative to the sugammadex group were as follows:
pre- vs. post operative INR: 1.6 ± 0.7 and 1.5 ± 0.5, re-
spectively (p = 0.71); pre- vs. post operative aPTT ratio:
1.3 ± 0.4 vs. 1.3 ± 0.2, respectively (p = 0.43).
We also investigated the existence of correlations be-
tween recovery time and BMI, MELD, duration of surgery,
WIT, CIT, PLT, fibrinogen, fluid balance, amount of intra-
venous fluids administered, liver function, creatinine clear-
ance pre or post-surgery and total amount of NMBDs
administered. No evidence for any strong correlations
were found using Pearson and Spearman tests (Table 3).
Only a positive trend was highlighted that might denote a
possible moderate correlation between sugammadex re-
covery time and: AST post OLT (r = 0.611, p = 0.003);
ALT post OLT (r = 0.50, p = 0.02); and amount of colloids
(r = 0.50, p = 0.02). In the neostigmine group, only length
of surgery showed a possible moderate correlation with
recovery time (r = 0.57, p = 0.009). No adverse events were
reported for either group.
Discussion
The present study constitutes the first randomized con-
trolled trial to evaluate sugammadex use following a
rocuronium bolus and continuous infusion in the OLT
setting. Our main finding is that, as was expected,
sugammadex results in a considerably shorter recovery
time than neostigmine, although the absolute value was
longer than expected, considering previously reported
data in the literature regarding other (non OLT) opera-
tive settings. The mean recovery time for sugammadex
in our population was 9.4 min, which is longer than that
reported in other studies after sevoflurane anaesthesia
[15], with 33% of patients requiring more than 10 min to
achieve a TOFR > 0.9. This should be taken into account
in clinical practice when waking patients up at the end
of transplantation. However, sugammadex retained its
well-known advantage as it regards recovery time over
neostigmine, which had a mean recovery time of 34.6
min. Of important note is the fact that 19% of the pa-
tients in the neostigmine group required more than 60
min to recover from NMB, with a maximum value that
exceeded 100min.
Previous studies using rocuronium-sugammadex in pa-
tients affected by liver disease undergoing hepatic resec-
tion have demonstrated the well-known advantages of
sugammadex over neostigmine in the above-mentioned
setting [24, 25]. However, OLT differs greatly from general
surgery or liver resection surgery; for instance, blood loss
and duration of surgery may be significantly greater in
OLT. Furthermore, the severity of the liver disease can
play a role: the patients enrolled onto our study were more
critical than those enrolled by Fujita and colleagues [24]
Table 1 Demographics, biometrics, pre and postoperative liver and
renal function data. Values are expressed as the mean± SD unless
otherwise indicated. Postoperative data refers to laboratory tests






female, n and (%) 7 (33) 8 (40)
male, n and (%) 14 (67) 12 (60)
Age (years) 54.1 ± 9.8 54.1 ± 10.4
Weight (kg) 73.9 ± 14.2 73.1 ± 14.7
Height (m) 1.7 ± 0.1 1.7 ± 0.1
BMI (kg/m2) 25.2 ± 4.2 25.3 ± 3.9
Liver disease:
HBV-related cirrhosis
± HCC, n and (%)
2 (9.5) 0 (0)
HCV-related cirrhosis
± HCC, n and (%)
9 (42.8) 6 (30)
Alcohol-related cirrhosis
± HCC, n and (%)
6 (28.5) 6 (30)
Alchohol + HBV-related
cirrhosis, n and (%)
1 (4.7) 0 (0)
Alchohol + HCV-related
cirrhosis, n and (%)
0 (0) 4 (20)
HIV coexists, n and (%) 2 (9.5) 2 (9.5)
Other disease, n and (%) 3 (14.2) 4 (19)
Pre-operative liver and renal
function
p
MELD 16.8 ± 7.3 21.4 ± 9.1 0.1
AST (IU/l) 67.4 ± 39.1 122.8 ± 62 0.15
ALT (IU/l) 48.6 ± 41.1 89.7 ± 168.7 0.30
LDH pre-op (IU/l) 485.3 ± 191.5 457.8 ± 368.4 0.93
TBil (mg/dl) 6.7 ± 10.2 11.5 ± 13.4 0.45
DBil (mg/dl) 3.8 ± 6.1 6.1 ± 8.2 0.6
GGT (IU/l) 155 ± 340 75 ± 74 0.34
Albumin (mg/dl) 29.9 ± 6.2 31 ± 6.4 0.27
ClCr (ml/min) 86.5 ± 34.9 80.7 ± 36.8 0.61
Postoperative liver and renal function
AST (IU/ml) 1246 ± 1060 1688 ± 1508 0.29
ALT (IU/m) 654 ± 348 1346 ± 1594 0.07
LDH (IU/l) 2986 ± 1699 3957 ± 5804 0.49
TBil (mg/dl) 4.6 ± 2.5 6.9 ± 4.6 0.25
DBil (mg/dl) 3.2 ± 2 4 ± 3.2 0.65
GGT (IU/l) 58 ± 47 77 ± 56 0.27
Albumin (mg/dl) 19.8 ± 8 21.3 ± 6 0.82
ClCr (ml/min) 86.2 ± 30.7 72.2 ± 29.1 0.14
Abbreviations: BMI body mass index; MELD Model for End-Stage Liver Disease;
AST aspartate aminotransferase; ALT alanine aminotransferase; LDH lactate
dehydrogenase; TBil total bilirubin; DBil direct bilirubin; GGT gamma glutamyl-
transferase; ClCr estimated creatinine clearance (Cockroft-Gault formula used)
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and Abdutalif and colleagues [25] given their end-stage liver
disease (see the AST and ALT, bilirubin, serum albumin and
gamma glutamyl transferase values for example). In addition,
in the study by Fujita and colleagues, rocuronium continuous
infusion was targeted at obtaining T1 at TOF-stimulation, a
lower degree of NMB compared with our study, in which
deep NMB was achieved. These findings probably explain
the lower total dose of rocuronium infused in the above-
cited studies compared with our study.
Moreover, some evidence exists in the literature, con-
sidering various operative settings, to suggest that higher
total doses of rocuronium may be related to longer
recovery times; for example, Llaurado and colleagues de-
scribed a relationship between total rocuronium dose
and recovery time in a cohort of obese patients following
sugammadex administration [27]. Abdulatif and col-
leagues demonstrated the safe use and efficacy of sugam-
madex in the specific setting of cirrhotic patients with a
mean recovery time of 3.1 min [25]. The higher
rocuronium dosage used in the present study compared
with that by Abdulatif et al. could, in part, explain our lon-
ger recovery times. It should also be noted, however, that
the total duration of surgery required in our setting was
significantly longer than in the cases considered by Abdu-
latif et al.; we administered rocuronium via continuous
infusion at a fixed dose (in accordance with the study
protocol), a modality that could have overexposed the pa-
tient (for instance in the anhepatic phase) to the NMBD.
In the literature, an experimental study has investi-
gated the possibility of interactions occurring between
sugammadex and other drugs, and indeed it has been
found that flucloxacillin, fusidic acid and tormifene have
the potential to exert a displacement interaction with
sugammadex [28]. An in vitro study has also demon-
strated possible interferences between corticosteroids
and sugammadex action [29], whereas, Rezonja and col-
leagues, published an in vivo randomized controlled trial
in which they demonstrated that dexamethasone does
not alter sugammadex recovery time [30]. The opposite
was later concluded by Saleh and colleagues, who, evalu-
ating dexamethasone use for the prevention of post-
operative nausea and vomiting in children undergoing
strabismus surgery, demonstrated a delayed reversal of
rocuronium-induced NMB by sugammadex [31]. To
make the picture even more complex, it was recently
demonstrated by Ozer and colleagues that sugammadex
recovery times are reduced when administered in con-
junction with steroids, especially desamethasone [32].
All the patients in our study received a high intraoper-
ative dose (3.5–5 mg/kg) of methylprednisolone hemi-
succinate as immunosuppressant just before hepatic
vascular unclamping. In an experimental study on rats,
Saleh and colleagues evaluated the effect of very high
(non clinical) steroid dosages on the resulting behaviour
Table 2 Intraoperative data. Cardiac output and index were evaluated at reversal administration. Values are expressed as the
mean ± SD.
Sugammadex (n = 21) Neostigmine (n = 20) p
Duration of surgery (min) 402 ± 54 378 ± 102 0.41
Intra-op blood losses (ml) 7278 ± 6346 6039 ± 5608 0.56
PRC (ml) 1700 ± 1325 2407 ± 2475 0.28
FFP transfused (ml) 2981 ± 2492 2933 ± 3207 0.9
Salvaged blood transfused (ml) 1825 ± 1750 1650 ± 2147 0.81
Fluid balance (ml) 3374 ± 2512 1612 ± 1915 0.07
CIT (h) 8.3 ± 1.9 8.8 ± 2.1 0.73
WIT (min) 46.6 ± 16.5 39 ± 14.8 0.12
Total crystalloid infusion (ml) 8585 ± 3224 6582 ± 3095 0.06
Total albumin 4% infusion (ml) 2612 ± 1314 1982 ± 1199 0.14
Cardiac Output (l/min) 8.6 ± 2.2 8.8 ± 2.8 0.80
Cardiac Index (l/min/m2) 4.8 ± 1.2 4.8 ± 1.7 0.91
Abbreviations: PRC packet red blood cell; PLT platelets; FFP fresh frozen plasma; CIT cold ischaemia time; WIT warm ischaemia time
Fig. 2 Recovery time for sugammadex and neostigmine. Mean value
was 9.4 vs. 34.6 minutes for sugammadex and neostigmine
respectively (p < 0.0001)
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of sugammadex on rocuronium, but, once again, no sig-
nificant affect was detected [31]. Human studies into the
potential interference between corticosteroids and
sugammadex action are still lacking.
Kandemir and colleagues, in their animal study, found
that when methylprednisolone was used in combination
with remifentanil, sugammadex action was prolonged
due to a synergistic effect [33]. This result contrasts with
that reported by Zwiers and colleagues, in which these
two drugs were used individually and no alterations in
the clinical effect of sugammadex were reported [28].
However, in the different context of OLT, the pharma-
cokinetics of remifentanil are best described by a two-
compartment model that takes into account a central
and a peripheral volume of distribution. In addition, the
functional status of the liver did not significantly affect
the pharmacokinetics of remifentanil, although body
weight also influences the volumes of distribution with
implications for the pharmacokinetic behaviour of remi-
fentanil [34].
These findings are very intriguing and require further
research since the volume of distribution after OLT may
be deeply altered – often increased – and could, therefore,
lead to the redistribution of remifentanil and, conse-
quently, to the possible interaction between remifentanil-
methylprednisolone and sugammadex function following
liver reperfusion. However, this is only a speculative pro-
posal to explain the longer recovery times of sugammadex
in OLT.
To understand the unexpected relatively long recovery
time of sugammadex in more detail, we performed Pear-
son and Spearman tests to explore the possible correla-
tions between peri-operative variables and recovery time,
but no statistically significant strong correlations were
found (Table 3). However, postoperative liver AST and
ALT, and the amount of intra-operative colloids were
found to show a positive trend with shorter sugamma-
dex recovery times, denoting a possible moderate correl-
ation. Intra-operative colloids may influence cardiac
output. Thus, higher amounts of colloid administration
could result in a faster redistribution of rocuronium
from the peripheral compartment into the central one,
where it is then encapsulated by sugammadex and elimi-
nated by the kidney. It may also be possible that graft
function influences sugammadex performance, since
rocuronium is mostly eliminated by liver uptake, thus
Table 3 Correlations between recovery time and pre, intra and postoperative values. “Pre” refers to pre-operative while “post” to
postoperative value.
SUGAMMADEX NEOSTIGMINE
Pearson p Spearman p Pearson p Spearman p
BMI −0.304 0.180 − 0.342 0.129 −0.119 0.618 0.105 0.659
MELD 0.195 0.454 0.046 0.862 − 0.416 0.076 −0.399 0.091
AST pre 0.275 0.253 0.341 0.152 −0.191 0.419 −0.146 0.537
AST post 0.611 0.003 0.569 0.007 0.088 0.710 0.330 0.154
ALT pre 0.1633 0.504 0.329 0.167 −0.165 0.486 −0.267 0.253
ALT post 0.4960 0.022 0.345 0.125 0.071 0.764 0.257 0.273
GGT pre −0.061 0.815 0.335 0.186 0.429 0.075 0.100 0.692
GGT post −0.242 0.317 0.037 0.878 −0.052 0.831 −0.012 0.960
ClCr pre 0.378 0.090 0.296 0.191 −0.124 0.601 −0.021 0.929
ClCr post −0.232 0.311 −0.176 0.445 0.019 0.936 0.068 0.777
Length surg 0.293 0.198 0.357 0.113 0.570 0.009 0.341 0.142
Blood loss 0.423 0.063 0.355 0.123 0.239 0.355 0.169 0.513
Fluid balance 0.293 0.270 0.209 0.436 −0.131 0.630 −0.198 0.454
CIT −0.151 0.515 −0.152 0.511 −0.084 0.726 0.083 0.726
WIT 0.461 0.036 0.372 0.097 −0.054 0.821 −0.049 0.837
Tot NMBA 0.271 0.235 0.182 0.430 0.135 0.582 0.268 0.267
Crystalloids 0.093 0.697 0.045 0.852 0.199 0.443 0.202 0.434
Colloids 0.502 0.024 0.271 0.248 0.041 0.875 0.091 0.727
CO 0.449 0.047 0.363 0.115 −0.051 0.845 0.015 0.957
CI 0.404 0.086 0.349 0.143 −0.062 0.813 0.091 0.727
Abbreviations: BMI body mass index; MELD Model for End-Stage Liver Disease; CIT cold ischaemia time; WIT warm ischaemia time; ClCr clearance creatinine
(Cockroft Gault); CO cardiac output; CI cardiac index; NMBA neuromuscular blocking agent; AST alanine aspartate transferase; alanine amino transferase; GGT
gamma glutamyl transferase
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contributing to the elimination of NMB by adding to the
action of sugammadex. However, the sample size of this
study was not calculated with the view of investigating
these potential interactions with sugammadex, so further
randomized controlled trials of adequate numerosity will
be required to understand these possibilities any further.
The pharmacokinetics of rocuronium are highly variable
in cirrhotic patients, with some authors noting longer on-
set and offset times [35–37]. Given this premise, a phys-
ician might argue against its use in patients undergoing
OLT, in favour of a non-organ-specific metabolized NMB,
such as cisatracurium, with a more favourable metabolism
[38]. However, the possibility of rapidly reversing rocuro-
nium activity with sugammadex offers advantages in the
context of fast track surgery in general and in OLT in par-
ticular, providing anaesthetists with the possibility of extu-
bating the patient in the operating room or shortly after
intensive care admission. There is also evidence that early
extubation after OLT improves patient outcome and saves
costs [17, 18]. However this fast track approach needs to
fulfil some important criteria, such as haemodynamic and
respiratory stability, no expected graft dysfunction, no
large intraoperative blood loss, normal pH, normothermia,
uncomplicated surgery, and good teamwork between sur-
geons, anaesthesiologists and intensivists [39]. Obviously,
complete recovery from NMB to avoid respiratory failure
due to PORC is mandatory and rocuronium-sugammadex
use provides a valid option, especially because extubation
failure after surgery and the need for reintubation repre-
sent an important mortality risk factor [40].
A possible negative consequence of sugammadex use
may become apparent in the case that urgent surgery is
required within 24 h of transplant as some residual rever-
sal activity may still be present due to the continual circu-
lation of sugammadex in the blood. In this case, rapid
sequence induction is unavoidable, necessitating the use
of succynilcholine with its well-known side-effects .
An increased risk of bleeding after sugammadex admin-
istration has been reported by De Kam et al. [41] They de-
scribed an increase in INR and the aPTT ratio time after
sugammadex administration, albeit in the absence of any
clinical impact. More recent evidence supports the older
findings by De Kam [42, 43]. Our results did not reveal
any increases in coagulation laboratory test values, con-
firming no clinically significant augmented bleeding after
sugammadex has been administered.
In light of the results of our study, it may be advisable
to administer sugammadex with a reasonable margin of
time (i.e., 15 min) before the actual extubation of the
OLT recipient patient.
A limitation to our study should also be noted; all the
OLT patients included in the study were characterised
by haemodynamic stability, so our findings can’t be ex-
tended to patients with poor haemodynamic conditions.
Anaesthetic management can be an important source
of bias during OLT, but anaesthetic conduct in our
study adhered very strictly to an internal protocol ap-
plied to all OLT. As a consequence, anaesthetic variabil-
ity was minimal as the protocol regarded all aspects not
related to NMB management. This ‘standardised’ anaes-
thetic practice in OLT translated into the lack of any
statistically significant differences in intra-operative vari-
ables (such as bleeding, fluids or transfusions) between
the sugammadex and neostigmine group. Additionally,
all OLT were performed with the same surgical team
dedicated to solid organ transplant surgery, further de-
creasing the potential for treatment bias, such as differ-
ent surgery durations times.
Conclusion
The performance of sugammadex was superior to that
of neostigmine in terms of recovery time in the OLT set-
ting. Sugammadex offers anaesthetists an efficacious and
safe reversal option that can facilitate a fast track recov-
ery protocol including more frequent extubation in the
operating room that may lead to improved outcomes.
However, anaesthetists must bear in mind the need for
longer sugammadex recovery times compared with other
surgical settings and be aware that NMT monitoring is
mandatory.
Further randomized clinical trials are needed to fur-
ther characterize sugammadex in the setting of liver
transplant, including its longer recovery time versus
other surgical populations, and the potential role of ste-
roids on its clinical effect.
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